Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?

Consolidation anti-programmed death-ligand 1 has become a new standard of care in unresectable stage III non-small cell lung cancer (NSCLC) following chemo-radiotherapy (CTRT), based on the results of two phase III trials. Advances remain however needed, in particular to reduce the risk of distant r...

Descripción completa

Detalles Bibliográficos
Autores principales: Remon, Jordi, Levy, Antonin, Singh, Pawan, Hendriks, Lizza E. L., Aldea, Mihaela, Arrieta, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340398/
https://www.ncbi.nlm.nih.gov/pubmed/35923929
http://dx.doi.org/10.1177/17588359221113268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340398/
https://www.ncbi.nlm.nih.gov/pubmed/35923929
http://dx.doi.org/10.1177/17588359221113268

Ejemplares similares